<DOC>
	<DOCNO>NCT00031434</DOCNO>
	<brief_summary>The purpose study evaluate ganciclovir metabolize administer intravenously ( needle insert vein ) follow valganciclovir syrup , give mouth newborn young infant symptoms congenital ( present birth ) cytomegalovirus ( CMV ) disease . The study also seek identify dose valganciclovir provide comparable blood concentration ganciclovir present blood newborn symptomatic congenital CMV disease . All study participant receive 6 week antiviral therapy ( define ganciclovir and/or valganciclovir ) . Infants 0 30 day old participate study 2 year .</brief_summary>
	<brief_title>Valganciclovir Congenital CMV Infants</brief_title>
	<detailed_description>Recent trial demonstrate ganciclovir treatment neonate symptomatic congenital cytomegalovirus ( CMV ) disease involve central nervous system result improve hearing function ( maintenance normal hearing function ) prevent hear deterioration 6 month . Furthermore , ganciclovir therapy may prevent hear deterioration 1 year . Ganciclovir recipient also rapid resolution transaminase elevation great degree short term growth weight head circumference compare untreated patient . Valganciclovir , oral product ganciclovir , develop syrup formulation present opportunity treat longer , pharmacokinetic data need infant first assure correct dose utilized . This Phase I/II , multi-center , open-label trial ass safety/tolerability pharmacokinetics ( ganciclovir concentration ) follow administration oral valganciclovir neonate symptomatic congenital CMV disease . A total 24 patient evaluate . All patient enter study receive 6 week ( 42 day ) antiviral therapy ( define ganciclovir and/or valganciclovir ) . Two different dose determination strategy apply protocol . The first individual patient approach . The second group dose modification strategy . The primary endpoint pharmacokinetics ganciclovir follow administration oral valganciclovir syrup . The pharmacokinetics assess population approach PK data analysis . Secondary endpoint : pharmacokinetics valganciclovir follow administration oral valganciclovir ; correlation ganciclovir plasma concentration follow administration intravenous ganciclovir oral valganciclovir syrup CMV whole blood viral load ; lack vomit and/or diarrhea associate administration oral valganciclovir syrup ; assessment toxicity , neutropenia , associate administration oral valganciclovir syrup .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Signed informed consent parent ( ) legal guardian ( ) . Culture confirmation cytomegalovirus ( CMV ) urine throat swab specimen . Symptomatic congenital CMV disease , manifest one following : Thrombocytopenia Petechiae Hepatomegaly Splenomegaly Intrauterine growth restriction Hepatitis ( elevate transaminase and/or bilirubin ) Central nervous system involvement CMV disease ( microcephaly , radiographic abnormality indicative CMV CNS disease , abnormal CSF index age , chorioretinitis , hear deficit detect brainstem evoke response , and/or positive CMV PCR CSF ) Less equal 30 day age study enrollment . Weight study enrollment great equal 1800 gram . Gestational age great equal 32 week . Imminent demise . Patients receive antiviral agent immune globulin . Gastrointestinal abnormality might preclude absorption oral medication ( e.g. , history necrotizing enterocolitis ) . Creatinine clearance &lt; 10mL/min/1.73 square meter time study enrollment . Infants know born woman HIV positive ( HIV test require study entry ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Days</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Valganciclovir , congenital cytomegalovirus , ganciclovir</keyword>
</DOC>